Tag Archives: Fighting Cancer

Alternative Cancer Treatment, Cancer Care Tips, Cancer Research, Stage Four Cancer Treatment

What to Understand about Metastatic Cancer

Understanding Stage IV
Understanding Stage IV

Have you heard reference to the term “metastatic cancer” but you’re unsure what it means? It may sound like a technical term, but it’s a relatively straightforward concept. Here are some facts to help demystify the issue.

Metastatic cancer is also called “stage IV” or “advanced”

All three terms refer to cancer that has spread from its original location to other parts of the body. Metastasis is the process by which cancer cells migrate via the blood or lymph system.

Metastatic tumors are treated the same as the original tumors

The tumors are called by the same name and treated with the same protocols as the primary cancer. If the original location cannot be determined, it’s considered to be carcinoma of unknown primary origin, or CUP. The patient undergoes a series of diagnostic tests to help doctors zero in on possible locations of the main tumor as well as appropriate courses of treatment.

Different forms of cancer are more likely to travel to particular areas

For example, breast cancer most commonly metastasizes to the lungs or bones. In addition, stage IV cancer may spread to one or several additional locations.

Metastatic cancer can be successfully treated

While the spread of tumors is a serious development, medical advances have made significant improvements in life expectancy for stage IV patients. Ongoing tests and studies continue to make breakthroughs in effective protocols.

Our state-of-the-art, non-toxic immunotherapy protocols boost your body’s own ability to fight cancer at any stage. Contact us to learn more about our comprehensive, individualized treatment programs at Issels®.

Alternative Cancer Treatment, Breast Cancer, Cancer Research, News

Leukemia Virus in Cattle and Potential Breast Cancer Connection Revealed

Hypothermia To Fight Cancer?
Breast Cancer

While breast cancer incidence rates in the United States have been dropping since 2000, it’s estimated that approximately 40,000 women will die from the disease this year. Researchers have recently discovered an unexpected risk factor that may surpass known ones such as obesity and postmenopausal hormone use.

Bovine leukemia virus (BLV) causes malignant lymphoma and lymphosarcoma in up to five percent of infected beef and dairy cattle. Until recently, the medical community believed that BLV could not be transmitted to humans.

That idea was shattered by a University of California-Berkeley team led by Professor Gertrude Buehring of its School of Public Health. In 2014, the group of researchers turned up the first-ever evidence of BLV in humans.

Prof. Buehring then had her team turn their attention to investigating a link between BLV and breast cancer. Samples were obtained from 239 women, some of whom were breast cancer patients. BLV was discovered in 59 percent of samples from the latter, compared to 29 percent in those who were cancer-free.

At this point it’s not known how BLV infects breast tissue, although Prof. Buehring speculates that possible causes are unpasteurized milk, unprocessed meat or human-to-human transmission. She also states that there is no proof at this point that BLV is a direct cause of breast cancer. Further studies will focus on determining whether BLV is present before tumors develop.

Breast cancer patients are among the thousands who have received treatment with the non-toxic personalized therapies at our Issels® immuno-oncology clinics. Visit our website to view testimonials and subscribe to our newsletters.

Cancer Care Tips, Cancer Research, Living with Cancer

Incidence of Lung Cancer in Non-Smokers Rises to 15%

Lung Cancer On The Decline
Rise in Lung Cancer in Non Smokers

Smoking tobacco has long been a known risk factor for lung cancer. Surprisingly, as smoking rates have declined, non-smokers have accounted for a higher percentage of lung cancer cases. In addition, these patients are more likely to be women.

Data comes from studies in Great Britain and the United States involving non-small cell cancer, which constitutes 85 to 90 percent of all lung cancer cases. This type is aggressive and usually detected at a later stage, particularly in non-smokers who are not screened as often due to fewer risk factors.

Over a seven-year period, British researchers discovered that the percentage of never-smokers with lung cancer more than doubled from 13 percent to 28 percent. Subjects included 2,170 patients between 2008 and 2014.

Their American counterparts had similar results in a study of lung cancer patients between 1990 and 2013. According to lead researcher Dr. Lorraine Pelosof, nine percent of non-small cell patients between 1990 and 1995 were never-smokers. In the period of 2011-2013, the percentage had grown to nearly 15 percent.

At present, researchers are stumped as to the reason for these increases, or why women are more susceptible. Ongoing studies are focusing on genetic risk and family history as possible causes in the absence of tobacco use. Dr. Pelosof also commented on the need to confirm her team’s findings, noting limitations such as the smoking history of subjects being self-reported.

Our Issels® immuno-oncology protocols take into account your lifestyle, genetic history, environment and other factors that affect your case. The result is a personalized, non-toxic course of treatment that addresses your specific needs. Visit our website to learn more.

Alternative Cancer Treatment, Cancer Research, Immuno-Oncology

Foundation Works to Create Pancreatic Cancer Awareness

Creating Awareness
Creating Awareness

Next week in November we celebrate Pancreatic Cancer Awareness Month. Did you know that in the U.S. pancreatic cancer comprises just 3 percent of cancer cases, yet it accounts for 7 percent of fatalities? For those affected by the disease, information and support can be harder to find compared to more common forms of cancer.

When Herb Kosten passed away in 2003, his family decided to form an organization to provide support and awareness for pancreatic disease in the Memphis area. The foundation has also provided half a million dollars in research funding to a local university.

As the late Kosten’s brother Alan says, the family could find no information about pancreatic cancer besides what the doctor told them.

As proponents of individualized care and integrative immuno-oncology, we at Issels® support the idea that fighting cancer takes groundbreaking research as well as a holistic approach to patient care. In addition to funding research at the University of Tennessee Health Science Center, the Herb Kosten Foundation hosts a support group for patients and family members. As the only pancreatic cancer support group within hundreds of miles, this provides a major source of comfort and empowerment to people who need it.

Treatment for pancreatic cancer often involves a difficult surgery that takes an entire day and often leads to complications. With a mortality rate around 90 percent, those affected by the disease seek to rally awareness and support for additional research in the quest for a cure.

At the Issels® Center for Integrative Immuno-Oncology, we continue to seek and improve personalized non-toxic treatments for pancreatic cancer and other aggressive forms of the disease. Contact us today to find out about our non-toxic treatments that combine immunotherapy and other alternative options available.

Alternative Cancer Treatment, Cancer Research, Living with Cancer

Sponge-Like Implant IDs Early Cancer Metastatic Cells for Earlier Treatment

Early Detection
Early Detection

An exciting new development in the battle against all forms of cancer has been announced by the journal Nature Communications. Engineers have devised a sponge-like apparatus that attracts the attention of cancer cells, causing them to cluster—not in an organism’s organ—but on the man-made apparatus. This represents a step toward controlling metastatic cells in patients suffering from breast, pancreatic, and prostate cancer in the future.

FDA Approved Material

The device is made of a sponge-like “biomaterial” that has already received FDA approval for use in medical devices. Although it has only been used in lab rodents with breast cancer, the material could be tested in humans very soon. It works like a decoy to attract cancer cells and distract them from clustering in the body’s organs. So far, the results have been promising, and researchers are eager to begin the next phase.

An Effective Decoy

Ordinarily, cancer cells break loose from a tumor and are attracted to other areas in the body by immune cells. In the research results, these immune cells flocked to the sponge-like material, which is its natural reaction to any foreign body. The cancer cells end up being caught in the device and consequently reduced the numbers present at other sites, preventing them from colonizing other organs in the live test rodents and enabled researchers to extract them from the body while they remained inside the absorbent sponge-like material.

These findings are very positive and represent the ongoing strides that are being taken in the quest for a cancer cure. However, treatments like this will have to go through many stages before they can be made available to the public. To stay informed about the latest treatments available, and to receive more information about non-toxic cancer treatments, contact the Issels® Center for Immuno-Oncology.

Alternative Cancer Treatment, Cancer Research

Presence of the Protein CSN6 in Bowel Tumors Linked to a Poorer Bowel Cancer Prognosis

Protein Found In Bowel Tumors.
Protein Found In Bowel Tumors.

The Issels® Center for Immune-Oncology reports that a study conducted by researchers based at the University of Texas MD Anderson Cancer Center found that the presence of a specific protein molecule in bowel tumor samples indicate a less favorable prognosis.

Samples from patients suffering from bowel cancer were examined for a protein molecule called CSN6. This protein molecule is a regulator for multiple pathways. Among other things, it regulates some cell life cycles. Researchers looked at tissue samples from the actual tumor. In cases where the CSN6 molecule was found to be present, the colorectal cancer prognosis was determined to have a much shorter recurrence-free survival rate. In other words, where this protein molecule was found, those patients were more likely to have a recurrence of the colorectal cancer than in patients whose tumor samples did not contain the protein molecule.

These findings could be helpful in determining the best course of treatment for patients. The molecule itself could potentially be a future treatment target after further studies on its different pathways and possible molecular alterations. Bowel cancer patients can have the tumor tissue sample analyzed for the presence of the CSN6 molecule. If found, those patients would warrant closer monitoring and more frequent follow-up visits to catch future cancer recurrence as soon as possible.

Though these findings sound negative at first reading, they have very positive possibilities for colorectal patients. Using this discovery, higher risk patients could have a better chance of survival than before.

To learn more about the results of this study, or to find out more ways to handle a bowel cancer diagnosis, please contact us today at Issels®.